Digest Network Come funziona
Network
/
Società
Ba
Non verificato

Bayer

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

109 comunicati stampa

Guarda tutti i comunicati
04/12/2025
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Medicina - Varie
Sanità
Industria
Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome
Fonte
Bayer
Emittente
Business Wire
1.00
0
03/12/2025
Eventi
Industria
Scienza
Attrezzature medico-sanitarie
Medicina - Varie
Biotecnologia
Medicina nucleare
Farmaceutica
Salute
RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints
Fonte
Bayer
Emittente
Business Wire
1.00
0
02/12/2025
Industria
Scienza
Attrezzature medico-sanitarie
Medicina - Varie
Sanità
Biotecnologia
Farmaceutica
Vetrine/Shopping
Salute
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia
Fonte
Bayer
Emittente
Business Wire
1.00
0
02/12/2025
Bayer Crop Science Canada Launches EverGol Rise for Enhanced User Experience in Pulse Disease Control
Fonte
Bayer
Emittente
Business Wire
1.00
0
02/12/2025
Legge/Diritto
Scienza
Agricoltura
Materie prime
Farmaceutica
Salute
Associazioni/Professionisti
Bayer Welcomes Solicitor General Support for U.S. Supreme Court Review
Fonte
Bayer
Emittente
Business Wire
1.00
0
01/12/2025
Igiene alimentare
Sanità
Farmaceutica
Salute
Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations
Fonte
Bayer
Emittente
Business Wire
1.00
0
23/11/2025
Industria
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Cardiologia
Biotecnologia
Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention
Fonte
Bayer
Emittente
Business Wire
1.00
0
20/11/2025
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Sanità
Farmaceutica
Salute
Ottica
Oncologia
Industria
U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Fonte
Bayer
Emittente
Business Wire
1.00
0
10/11/2025
Scienza
Biotecnologia
Sanità
Salute
Fitness
Industria
Bayer Launches “Science Delivers” Campaign Celebrating the Transformative Power of Science
Fonte
Bayer
Emittente
Business Wire
1.00
0
06/11/2025
Biotecnologia
Sanità
Fitness
Salute
Mercato del lavoro
Dr. Judith Hartmann to Become New Chief Financial Officer of Bayer AG
Fonte
Bayer
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0